FDA Pulls Abbott’s Cylert From Market Due To Liver Toxicity
This article was originally published in The Pink Sheet Daily
Executive Summary
The ADHD drug will no longer be available after current supplies of pemoline generics are exhausted. Abbott stopped marketing the drug in May, citing low sales.
You may also be interested in...
Abbott Says Decision To Discontinue Cylert Stems From Demand, Not Safety
Significant decline in pemoline sales is reason behind the ADHD agent's discontinuation, not liver safety issues raised in a Public Citizen petition to FDA, Abbott says. Public Citizen seeks withdrawal of Cylert and generics; the petition references two analyses of pemoline conducted by FDA drug safety officer Graham.
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.
Indian Health Minister Asks Novartis to Stand Down On Gleevec Patent Fight
Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.